<DOC>
	<DOCNO>NCT02430259</DOCNO>
	<brief_summary>Tuberculosis ( TB ) remain important infectious disease world . Preventive treatment play important role successful control TB . For preventive therapy , three-month ( 12-dose ) regimen weekly rifapentine isoniazid ( 3RPT/INH ) recommend WHO non-inferiority , safety convenience compare 6~9 month regimen daily isoniazid monotherapy 3~4 month daily rifampicin monotherapy . And treatment completion rate high compare daily regimen . However , relevant study lack China TB burden high incidence rate 70/100 , 000 . And provision chemoprophylaxis recommend China currently . Silicosis high risk factor Mycobacterium tuberculosis infection . This open-label , randomize , Phase III clinical trial evaluate effectiveness tolerability 3RPT/INH prevent tuberculosis ( TB ) compare receive preventive treatment among silicotic patient .</brief_summary>
	<brief_title>Efficacy Weekly Rifapentine Isoniazid Tuberculosis Prevention</brief_title>
	<detailed_description>Tuberculosis ( TB ) remain important infectious disease world . Preventive treatment play important role successful control TB . For preventive therapy , three-month ( 12-dose ) regimen weekly rifapentine isoniazid ( 3RPT/INH ) recommend WHO non-inferiority , safety convenience compare 6~9 month regimen daily isoniazid monotherapy 3~4 month daily rifampicin monotherapy . And treatment completion rate high compare daily regimen . However , relevant study lack China TB burden high incidence rate 70/100 , 000 . Silicosis high risk factor Mycobacterium tuberculosis infection . This open-label , randomize , Phase III clinical trial evaluate effectiveness tolerability 3RPT/INH prevent tuberculosis ( TB ) among silicotic patient . The PRIMARY objective open-label , randomize , Phase III clinical trial evaluate effectiveness 3RPT/INH prevent TB compare receive preventive treatment among eligible silicotic patient . The SECONDARY objective : Describe safety profile 3RPT/INH China ( rate drug discontinuation reason due adverse drug reaction associate 3RPT/INH , rate grade 3 , 4 , 5 drug toxicity associate 3RPT/INH ) Describe treatment completion rate 3RPT/INH . Describe pattern antibiotic resistance M. tuberculosis isolate patient develop TB despite preventive treatment . Compare result QuantiFERON Gold In-Tube preventive treatment . For assessment primary outcome , development TB , sample size approximately 280 person per arm require 3 year follow-up .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Silicosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Individuals Silica exposure diagnose silicosis ; Age 18 65 year ; Willing provide sign informed consent , parental consent participant assent . Clinical culture confirm active TB ; A history treatment &gt; 14 consecutive day rifamycin &gt; 30 consecutive day INH previous 2 year ; A document history complete adequate course treatment active TB latent TB infection ; Allergy Isoniazid , Rifampin , Rifapentine ; Human immunodeficiency virus ( HIV ) infection ; History hepatitis B/C infection liver cirrhosis ; Serum Aspartic transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2x upper limit normal total bilirubin &gt; 2.5 mg/dL ; Receiving immunosuppressant biological agent ; Life expectancy &lt; 3 year ; Mental disorder ; Participated clinical trial recent three month ; Other condition investigates consider suitable participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>rifapentine</keyword>
	<keyword>isoniazid</keyword>
	<keyword>QuantiFERON Gold In-Tube</keyword>
	<keyword>tuberculin skin test</keyword>
</DOC>